However, researchers have also designed other molecules, including PRC2 activators, which target cancers governed by loss of function mutations, dual agents inhibiting EZH1/2, allosteric inhibitors binding to EED (which disrupt the EED–EZH2 protein–protein interaction), and compounds that induce the degradation of PRC2 constituent proteins. The gene discussed is EZH2; the disease is cancer.